Latest Clostridium Stories
VOORHEES, N.J., June 16, 2011 /PRNewswire/ -- Hypervirulent strains and increased frequency of Clostridium difficile infection (CDI) have resulted in more severe disease and increased costs to the healthcare system in recent years.
FRANKFURT, Germany, June 8, 2011 /PRNewswire/ -- Merz Pharmaceuticals today announced that new data on XeominÂ® (incobotulinumtoxinA), a botulinum toxin type A free from accessory (complexing) proteins, will be presented at the Movement Disorder Society's (MDS) 15th International Congress of Parkinson's Disease and Movement Disorders in Toronto, Canada.
SILVER SPRING, Md., May 27, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Dificid (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD). (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) Clostridium difficile (C.
MALVERN, Pa., May 20, 2011 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that the Company received a $7.5 million regulatory milestone from Pfizer, Inc.
EXTON, Pa., May 19, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced initiation of a Phase 2 dose-ranging clinical study to evaluate the safety, tolerability, and efficacy of VP 20621 for prevention of recurrence of Clostridium difficile infection (CDI) in adults previously treated for CDI. The objectives of this randomized, double-blind, placebo-controlled, dose ranging study are to evaluate the safety and tolerability of VP 20621 dosed orally for up to 14 days in...
BUFFALO, N.Y., May 12, 2011 /PRNewswire-USNewswire/ -- The warmer the summer, the more dead birds and fish you can expect to see along the shores of Lake Erie, according to a recent study led by Alicia Perez-Fuentetaja, research scientist of the Great Lakes Center at Buffalo State College and associate professor of biology.
SAN DIEGO, May 12, 2011 /PRNewswire/ -- Optimer Pharmaceuticals (NASDAQ: OPTR) today announced the presentation of an additional analysis of data from the company's two Phase 3 clinical trials of DIFICID(TM) (fidaxomicin), an investigational antibiotic for the treatment of Clostridium difficile Infection (CDI), at the American Geriatric Society (AGS) Annual Meeting held in National Harbor, Maryland. (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO) The analysis showed that above...
CHICAGO, May 9, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc.
SAN DIEGO, April 28, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc.
MARLBOROUGH, Mass., April 28, 2011 /PRNewswire/ -- Qteros, Inc., the developer of a unique and highly efficient Consolidated Bioprocessing (CBP) platform for the lowest-cost production of cellulosic ethanol, today announced its plans to present at various industry conferences throughout the month of May. Kevin A.
Clostridium botulinum is a gram-positive, rod-shaped bacterium that produces neurotoxins, known as botulinum neurotoxins types A-G, that cause the flaccid muscular paralysis seen in botulism. It is the main paralytic agent in botox and is commonly found in soil. It is also an obligate anaerobe, meaning oxygen is poisonous to the cells. Superoxide dismutase helps C. botulinum tolerate traces of oxygen. It was first recognized and isolated in 1895 by Emile van Ermengem. Subsequent outbreaks...